Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04369469 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT04369469 is a Phase 3 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 202 participants.
The verdict
NCT04369469, a Phase 3 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Participants were randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the participants) or BSC alone (1/3 of the participants). BSC consisted of medical treatment and/or medical interventions per routine hospital practice.
Interventions
- BIOLOGICAL Ravulizumab
- OTHER BSC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2020-05-10 |
| Est. Completion | 2021-04-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04369469
The ClinicalTrials.gov registry entry for NCT04369469 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ravulizumab is the first listed.
NCT04369469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04369469 about?
NCT04369469 is a clinical study titled "Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia". This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Participants were randomly assigned to receive rav...
What is the current status of trial NCT04369469?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2020-05-10. Estimated completion is 2021-04-08.
What interventions are being tested in trial NCT04369469?
The interventions under investigation include: Ravulizumab (BIOLOGICAL), BSC (OTHER).
Who is sponsoring clinical trial NCT04369469?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.